Physician profile
Mark A Goldstein
NPI 1932102357
$7,323.77
in general payments reported to CMS, 2019-2025
37 companies · $1,514 in 2025
The $1,514 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,345 · 2020: $325 · 2021: $401 · 2022: $1,053 · 2023: $1,356 · 2024: $1,329 · 2025: $1,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,101 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,100.61 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,438.44 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $1,226.53 | 2019-2025 | |
| Medtronic, INC. | $509.85 | 2021-2025 | Symplicity G3, Onyx Frontier |
| Abbott Laboratories | $460.56 | 2022-2023 | Thoratec Heartmate 3 Lvas Implant Kit, Gallant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.64 | 2021-2025 | Jardiance |
| Pfizer INC. | $319.74 | 2019-2025 | |
| Amgen INC. | $318.12 | 2019-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $277.11 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $229.23 | 2023-2024 | Mychoice Cdx, Precisetumor |
| Astrazeneca Pharmaceuticals Lp | $228.69 | 2019-2025 | Farxiga |
| Kestra Medical Technology Services, INC. | $228.26 | 2024 | Assure Wcd |
| Gilead Sciences, INC. | $222.00 | 2019 | |
| Merck Sharp & Dohme LLC | $215.03 | 2022-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $189.51 | 2019-2023 | Xarelto |
| Philips North America LLC | $155.95 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und, (5091) Amb Mon & Diag Und |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.